Inhibitor-Mediated Programming of Glycoformsbroad
IMProGlyco · Horizon Europe grant · 2025-02-01–2028-01-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2024-PATHFINDEROPEN-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2024-PATHFINDEROPEN-01-01. CORDIS record →
Objective
Site-directed mutagenesis revolutionised the study of proteins and enabled the development of protein-based therapeutics. Our long-term vision is to have equivalent impact through the precise manipulation of the glycans (carbohydrates) on cells and recombinant proteins that will enable the discovery and production of the next generation of therapies for cancer, neurodegeneration and other disease families. The glycans that are present on most proteins and cells have a substantial impact on their biological functions, yet the untemplated nature of their synthesis leads to inherent heterogeneity in both their structure and activity. This heterogeneity is very difficult to control, making it impossible to generate defined glycan ensembles with optimal activity using current technology. Here we present a radically new approach to the controlled manipulation of glycans that will be the functional equivalent of site-directed mutagenesis for manipulating proteins. We will use the delivery of computationally defined mixtures of enzyme-specific inhibitors to the site of glycan biosynthesis in the cell to tune the activity of glycosyltransferases. Our approach, termed Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) will provide an effective strategy to manipulate the glycosylation machinery and thereby generate proteins with defined ensembles of glycans. It will enable the production of precision glycan engineered therapeutic proteins and vaccines. Moreover, shaping cellular glycan profiles will aid discovery science to uncover glycan functions and improve therapeutic cells, such as those used in Chimeric Antigen Receptors cell Therapy (CAR-T). Our technology will be adaptable and expandable into other cell types and organisms allowing glycan shaping in all areas of eukaryotic cell biology to enable new biotechnological applications and fundamental studies of biology.
Beneficiaries (8)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| UNIVERSITY OF LEEDS | UK | coordinator | €1,127,462 | |
| UNIVERSITY OF YORK | UK | participant | €794,641 | |
| UNIVERSITAET FUER BODENKULTUR WIEN | AT | participant | €441,975 | |
| HUN-REN TERMESZETTUDOMANYI KUTATOKOZPONT | HU | participant | €401,500 | |
| OSLOMET - STORBYUNIVERSITETET | NO | participant | €380,106 | |
| GLYCOSELECT LTD | IE | participant | €205,832 | |
| OSLO UNIVERSITETSSYKEHUS HF | NO | participant | €78,349 | |
| CENTRE FOR PROCESS INNOVATION LIMITED LBG | UK | participant | €10,662 |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.